Department of Internal Medicine.
Oncologist. 2013;18(12):1248-55. doi: 10.1634/theoncologist.2013-0111. Epub 2013 Nov 20.
Patients with type 2 diabetes have increased cancer risk and cancer-related mortality, which can be reduced by metformin treatment. However, it is unclear whether metformin can also modulate clinical outcomes in patients with cancer and concurrent type 2 diabetes.
A meta-analysis of 20 publications that included 13,008 subjects was performed to investigate the association between metformin and overall survival (OS) as well as cancer-specific survival (CSS) in patients with cancer and concurrent type 2 diabetes.
We found that there was a relative survival benefit associated with metformin treatment compared with treatment with other glucose-lowering medications in both OS and CSS (hazard ratio [HR] = 0.66; 95% confidence interval [CI]: 0.55-0.79 and HR = 0.62; 95% CI: 0.46-0.84, respectively). These associations were also observed in subgroups by cancer type and country.
These results suggest that metformin is the drug of choice in the treatment of patients with cancer and concurrent type 2 diabetes.
研究癌症合并 2 型糖尿病患者中二甲双胍与总生存(OS)和癌症特异性生存(CSS)的关系。
对纳入 13008 例患者的 20 项研究进行荟萃分析,以探讨癌症合并 2 型糖尿病患者中二甲双胍与 OS 和 CSS 的关系。
我们发现,与其他降糖药物相比,二甲双胍治疗与 OS 和 CSS 相关的生存获益相关(风险比 [HR] = 0.66;95%置信区间 [CI]:0.55-0.79 和 HR = 0.62;95% CI:0.46-0.84)。这些关联在按癌症类型和国家划分的亚组中也观察到。
这些结果表明,二甲双胍是治疗癌症合并 2 型糖尿病患者的首选药物。